Answers are grounded in this paper and cite their sources.
Background and aims Gout frequently co-occurs with steatotic liver disease, but its direct hepatotoxic effect beyond obesity remains contentious. We aimed to elucidate the independent association between gout and hepatic fibro-inflammation, particularly in subclinical cases with normal alanine aminotransferase (ALT). Methods This multi-cohort study integrated a UK Biobank discovery cohort (N = 21,334) using MRI iron-corrected T1 (cT1) mapping, and a multicenter clinical validation cohort (N = 512) using Transient Elastography (FibroScan) to measure liver stiffness (LSM). Multivariable regression and causal mediation analyses dissected “obesity-dependent” versus “independent” pathways. Results Gout patients exhibited significantly elevated liver fibro-inflammation and steatosis across both cohorts. After full adjustment for metabolic confounders, gout was independently associated with liver injury in the UK Biobank ( β-cT1 = 6.41 ms, p = 0.025) and clinical cohort ( β-LSM = 1.21 kPa, p < 0.001). This association consistently persisted in non-obese patients with normal ALT (< 40 U/L), indicating occult injury. Mediation analysis revealed a “Double Hit” mechanism: 51.3% of the effect was obesity-mediated, while 48.7% was independent of body mass index. Conclusion Gout is an independent factor associated with subclinical hepatic fibro-inflammation, even in non-obese, normo-enzymatic patients. This challenges reliance on ALT screening alone, warranting the integration of sensitive liver health assessments into routine gout management.
No takes yet. Share an insight, caveat, or question.
Mei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: